Search PubMed⌕ Search

Biomedical subjects

J F Evans

Publications and source records attributed to J F Evans.

84 records · Page 5Linked to original sources
PubMed1980

Stage III carcinoma of the breast. A detailed analysis.

A ten-year study of Stage III breast carcinoma has been reviewed in detail. The single most dominant variable was axillary nodal involvement. Four hundred and thirty patients had nodal metastases, 58 patients did not. Four hundred and thirty patients with axillary nodal involvement had fiveand ten-year recurrence rates of 68 and 77%, while the survival rates were 41 and 21%, respectively. Life span was influenced by extent of nodal disease, being best for those with micrometastases only, and worse for those with four or more positive nodes. Skin edema, infiltration, or ulceration in the positive node group were grave signs. Muscle invasion or node matting, however, did not appear to influence length of life. Postoperative prophylactic therapy did not appear to affect survival rates. Radiation therapy alone did not influence either local recurrence or survival rates. Not enough time has elapsed to evaluate the results of postoperative chemotherapy. Patients who underwent oophorectomy and radiation therapy appeared to do better, but the number of patients was small. Of the 58 patients without nodal invasion, 82% were alive at five years and 75% were alive at 10 years. Grave signs did not influence the survival rate in this group. While the majority of patients with Stage III carcinoma had unfavorable variables, there were some patients who demonstrated a low recurrence rate and a long survival time. Aggressive treatment should be designed to save those patients who can be helped and to improve those patients whose life expectancy is limited. There is no place for timid initial treatment whether by operation or by irradiation. It must be given with intent to cure even though palliation is most often attained.

Adenocarcinoma↗
PubMed1968

Methodological study and a recommended technique for determining the euglobulin lysis time.

The euglobulin lysis time, which is widely used to measure blood fibrinolytic activity, is shown to be sensitive to the temperature and pH at which the euglobulin fraction of plasma is prepared and also to the type of anticoagulant employed and buffer in which it is suspended. A standardized method for performing the test, which controls these variables and has been found to yield reproducible results, is described. Since, at present, data obtained with this test by different laboratories are, for the reasons given, rarely comparable, it is hoped that the method outlined may be considered suitable for general adoption.

Anticoagulants↗
PubMedDate not supplied

A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.

The evolution of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy+ ++)indol-2-yl]- 2,2-dimethylpropanoic acid), 12, a potent, orally active leukotriene biosynthesis inhibitor is described. MK-0591 is currently undergoing clinical evaluation as a potential agent for the treatment of asthma and inflammatory bowel disease. It acts through a novel mechanism by a specific interaction with a membrane protein, 5-lipoxygenase activating protein (FLAP), which has been shown to be essential for LT synthesis in inflammatory cells. A brief comparison of its biological activity with that of its progenitors MK-886 and L-674,636 is described.

5-Lipoxygenase-Activating Proteins↗